David Harry Moore MD

Obstetrics & Gynecology•Indianapolis, IN

General Gynecology, Gynecologic Oncology

Gynecologic Oncology Specialists

Join to View Full Profile

8111 S Emerson AveSte 204Indianapolis, IN 46237
Phone+1 317-851-2555
Fax+1 317-851-2566

Education & Training

University of North Carolina HospitalsFellowship, Gynecologic Oncology, 1986 - 1988
Indiana University School of MedicineResidency, Obstetrics and Gynecology, 1982 - 1986
Indiana University School of MedicineClass of 1982

Certifications & Licensure

IN State Medical License 1982 - 2023
NC State Medical License 1986 - 1998

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Top MD Consumers Checkbook
Fellow (FACS) American College of Surgeons
Fellow (FACOG) American Congress of Obstetricians and Gynecologists
Join now to see all

Clinical Trials

Amifostine in Treating Women With Ovarian, Peritoneal, Cervical, Fallopian Tube, Uterine, or Endometrial Cancer Start of enrollment: 1998 Dec 01
Terminated
Phase 2
Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Cancer of the Vulva Start of enrollment: 2005 Jan 01
Completed
Phase 2
Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer Start of enrollment: 2005 Mar 21
Active, not recruiting
Phase 3
Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer Start of enrollment: 2009 Apr 01
Completed
Phase 3
Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer Start of enrollment: 2009 Mar 23
Active, not recruiting
Phase 3
YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy Start of enrollment: 2007 Sep 01
Terminated
Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer Start of enrollment: 2009 Jun 29
Active, not recruiting
Phase 3
Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy
ACTIVE_NOT_RECRUITING
PHASE3
Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma Start of enrollment: 2009 Nov 01
Terminated
Phase 3
Join now to see all

Publications & Presentations

PubMed

11 citations
Final survival analysis of topotecan and paclitaxel for first-line treatment of advanced cervical cancer: An NRG oncology randomized study.
Krishnansu S Tewari, Michael W Sill, Michael J Birrer, Richard T Penson, Helen Huang
Gynecologic Oncology. 2023-04-01
14 citations
Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology—Gynecologic Oncology Group Study 240 (NCT 00803062)
Krishnansu S. Tewari, Michael W. Sill, Bradley J. Monk, Richard T. Penson, David H. Moore
Molecular Cancer Therapeutics. 2020-08-26
399 citations
Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncolog...
Krishnansu S. Tewari, Michael W. Sill, Richard T. Penson, Helen Huang, Lois M. Ramondetta
Lancet. 2017-10-07

Committees

Member, Committee on Appropriateness Criteria, Expert Panel on Women's Imaging and Radiation Oncology-Gynecology, American College of Radiology 2015 - Present

Professional Memberships

American Society of Clinical Oncology - ASCO
Member
American College of Obstetricians and Gynecologists
Fellow
American College of Surgeons - ACS
Member